All News
David Liew drdavidliew ( View Tweet)
David Liew drdavidliew ( View Tweet)
RheumNow Live 2021 Now Available for All
RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).
Read Article
Risk Factors for Rheumatoid Arthritis-associated Interstitial Lung Disease
Sparks and colleagues have published a matched cohort analysis demonstrating risk factors that may augment the risk of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), especially the combination of obesity, high CRP, high MD-HAQ and >30 pack-year smoking h
Read Article
RheumNow Podcast – Uppers and Downers
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Links:
Golimumab Effective in non-radiographic Axial Spondyloarthritis
The GO-AHEAD study was designed to assess the long-term efficacy and safety of golimumab (GLM) in non-radiographic axial spondyloarthritis (nr-axSpA). After the 16-week, placebo [PBO]-controlled double-blind phase, 189/198 (95.5%) entered the long-term extension (OLE) for 36 weeks wherein G
Read Article
Diagnostic Delay in Spondyloarthritis
Literature review and metanalysis of many studies suggests that significant delay to diagnosis in axial spondyloarthritis (axSpA) exist, are longer than other rheumatic diseases and have not changed over time.
Read Article
Increased Risk of COPD in ACPA+ Pre-RA Patients
The lung and its pathology is uniquely tied to rheumatoid arthritis (RA) and its pathogenesis. A new study shows that elevation of anti–citrullinated protein antibodies (ACPAs) before diagnosis of RA increases the risk of developing chronic obstructive pulmonary disease (COPD
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Broadalumab Efficacy in Axial Spondyloarthritis
Broadalumab (Siliq), an anti-interleukin-17 receptor A monoclonal antibody, is currently FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axial spondyloarthritis (axSpA).
Read Article
RheumNow Podcast – Combination Biologics
Dr. Jack Cush serves up this week's news and articles from RheumNow.com.
Read Article
IL-23 Targeting for Enthesitis in Psoriatic Arthritis
Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found.
Read Article
Can Targeting RANKL in RA Heal Erosions?
Treatment with denosumab (Prolia) helped heal bone erosions over 2 years among patients with rheumatoid arthritis whose disease activity was well controlled, researchers reported.
Read Article
Aortic Calcification and Lumbar Fracture Risk in Older Men
Fractures of the spine and abdominal aortic calcification (AAC) can both be visualized with spinal imaging; a new report shows that finding both radiographic vertebral fracture and AAC on the same lateral spine images may predict the risk of future incident major osteoporotic fracture i
Read Article
Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease
There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.
Read Article
Potent Topical Corticosteroids and the Risk of Osteoporotic Fractures
JAMA Dermatology has published a Danish national cohort study showing that potent topical corticosteroid use was associated with an increased risk of osteoporosis and major osteoporotic fractures with a dose-response association for cumulative use.
Read Article
Diagnosis & Treatment of Osteoarthritis Reviewed
Katz, Arant and Loeser have published a comprehensive open-read overview of osteoarthritis (OA) of the hip and knee in JAMA; underscoring the impact, advances, disappointments and guidelines put forth.
Read Article
Lung Preservation with Tocilizumab in Early Systemic Sclerosis
Arthritis & Rheumatology has published the results of a subanalysis from tocilizumab (TCZ) clinical trials showing that Il-6 inhibition was associated with preservation of lung function patients with early systemic sclerosis (SSc).
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)